- Home
- CYBN vs MIST Comparison
CYBN vs MIST Comparison
Compare CYBN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- MIST
- Stock Information
- Founded
- CYBN 2019
- MIST 2003
- Country
- CYBN Canada
- MIST Canada
- Employees
- CYBN N/A
- MIST N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- MIST Health Care
- Exchange
- CYBN Nasdaq
- MIST Nasdaq
- Market Cap
- CYBN 147.4M
- MIST 163.2M
- IPO Year
- CYBN N/A
- MIST N/A
- Fundamental
- Price
- CYBN $6.34
- MIST $1.85
- Analyst Decision
- CYBN Strong Buy
- MIST Strong Buy
- Analyst Count
- CYBN 3
- MIST 3
- Target Price
- CYBN $85.00
- MIST $6.33
- AVG Volume (30 Days)
- CYBN 1.0M
- MIST 1.4M
- Earning Date
- CYBN 11-17-2025
- MIST 11-11-2025
- Dividend Yield
- CYBN N/A
- MIST N/A
- EPS Growth
- CYBN N/A
- MIST N/A
- EPS
- CYBN N/A
- MIST N/A
- Revenue
- CYBN N/A
- MIST N/A
- Revenue This Year
- CYBN N/A
- MIST N/A
- Revenue Next Year
- CYBN N/A
- MIST N/A
- P/E Ratio
- CYBN N/A
- MIST N/A
- Revenue Growth
- CYBN N/A
- MIST N/A
- 52 Week Low
- CYBN $4.81
- MIST $0.63
- 52 Week High
- CYBN $13.88
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CYBN 48.10
- MIST 43.92
- Support Level
- CYBN $6.86
- MIST $1.76
- Resistance Level
- CYBN $8.00
- MIST $1.96
- Average True Range (ATR)
- CYBN 0.48
- MIST 0.10
- MACD
- CYBN 0.06
- MIST -0.02
- Stochastic Oscillator
- CYBN 27.48
- MIST 28.13
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).